Oncology
Supporting the Next Generation of Cancer Therapy Through Thoughtful Guidance
SDC’s dynamic oncology expertise spans various tumor types and oncology indications.
Oncology Expertise:
- Supported over 60+ Oncology studies in last 5 years
- All Phases and Study Designs: Adaptive design, Bayesian analysis, Early phase through global Phase 3 drug studies
- Full Service Clinical Trial Management across oncology indications including global trials
- Frequent interaction with global regulatory agencies
- 10+ regulatory submissions supported
- Rare disease and pediatric oncology expertise to understand the nuances needed
Oncology Indications
- Acute Myeloid Leukemia (AML)
- Advanced Solid Tumors
- B-Cell Lymphoma
- Bladder Cancer
- Bone Marrow Cancers
- Breast Cancers
- CHK1 Inhibitors
- Chronic Lymphocytic Lymphoma (CLL)
- Colorectal Cancer
- Endometrial Carcinoma
- Gastrointestinal Cancer
- Head and Neck Cancer
- Hematologic Malignancies
- Hepatocellular Cancer
- Hodgkin’s Lymphoma
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lung Neuroendocrine Tumors (NET)
- Melanoma
- Metastatic Breast Cancer
- Metastatic Solid Tumors
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Myelofibrosis
- Non-Hodgkin’s Lymphoma
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Pancreatic Cancer
- Perivascular Epithelioid Cell Neoplasm (PEComa)
- Prostate Cancer
- Recurrent Glioblastoma Multiforme (GBM)
- Renal Cancer
- Skin Cancer
- Small Cell Lung Cancer
- Soft Tissue Carcinomas
- Solid Tumors
- Spinal Tumors
- Thymus Neuroendocrine Tumors
- Uveal Melanoma